Weisensee, D.; Schüller, J.
In vitro cell transformation assays detect transformed cells that have acquired the characteristics of malignant cells and thus mimic one stage of the in vivo multi-step carcinogenesis model. These assays have been proposed as surrogate models for predicting the non-genotoxic carcinogenic potential of chemicals. A short-term cell transformation assay using v-Ha-ras transfected Balb/c 3T3 cells (Bhas 42 cells), the Bhas assay, which has not been used with cigarette smoke before, is capable of detecting, initiating, and promoting activities of chemical carcinogens. As the particulate phase of cigarette smoke (total particulate matter, or TPM) is known to induce tumors in vivo in the mouse skin painting assay, we investigated the responsiveness of the Bhas assay to form morphologically transformed foci in vitro when repeatedly challenged with TPM from a standard reference cigarette (3R4F). DMSO-dissolved TPM induced a dose-dependent increase of type III foci in the Bhas cell transformation assay. A significant increase in focus formation was observed in the promotion assay at sub-toxic doses between 5 and 60 microg TPM/ml (~16-fold). This novel in vitro assay using Bhas cells, which are regarded as initiated in the two-stage paradigm of carcinogenesis, is able to detect cell transformation induced by cigarette smoke condensate in a dose-dependent manner with a high dynamic range compared to the solvent control.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.